ATLANTA--(BUSINESS WIRE)--Holzer & Holzer, LLC is investigating whether certain statements issued by Akari Therapeutics, Plc (“Akari Therapeutics” or the “Company”) (NASDAQ: AKTX) complied with federal securities laws. On May 11, 2017, Akari Therapeutics announced that its Chief Executive Officer, Dr. Gur Roshwalb, had been placed on administrative leave while the Company’s Board of Directors reviewed whether he had any involvement in the release of a recently withdrawn Edison Investment Research report. The price of Akari Therapeutics common stock fell significantly following the news.
If you purchased Akari Therapeutics common stock between March 30, 2017 and May 11, 2017 and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at email@example.com or Marshall P. Dees, Esq. at firstname.lastname@example.org, or by toll-free telephone at (888) 508-6832 to discuss your legal rights.
Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.